Stephen G. Ward

Nitric oxide in inflammatory bowel disease: a universal messenger in an unsolved puzzle

In recent years, nitric oxide (NO), a gas previously considered to be a potentially toxic chemical, has been established as a diffusible universal messenger that mediates cell–cell communication throughout the body. Constitutive and inducible NO production regulate numerous essential functions of the gastrointestinal mucosa, such as maintenance of adequate perfusion, regulation of microvascular and epithelial permeability, and regulation of the immune response. Up‐regulation of the production of NO via expression of inducible nitric oxide synthase (iNOS) represents part of a prompt intestinal antibacterial response; however, NO has also been associated with the initiation and maintenance of inflammation in human inflammatory bowel disease (IBD). Recent studies on animal models of experimental IBD have shown that constitutive and inducible NO production seems to be beneficial during acute colitis, but sustained up‐regulation of NO is detrimental. This fact is also supported by studies on mice genetically deficient in various NOS isoforms. However, the mechanism by which NO proceeds from being an indispensable homeostatic regulator to a harmful destructor remains unknown. Furthermore, extrapolation of data from animal colitis models to human IBD is questionable. The purpose of this review is to update our knowledge about the role of this universal mediator and the enzymes that generate it in the pathogenesis of IBD.

PI 3-kinase: a pivotal pathway in T-cell activation?

Abstract Coupling and/or activation of phosphoinusitide 3-kinase (PI 3-kinase) commonly occurs following the triggering of T-cell surface molecules postulated to modulate early events in T-cell activation (e.g. CD28). Recent studies have revealed important add conflicting data as to the role of PI 3-kinase in T-cell costinualation following CD28 ligation. Here. Stephen Ward and colleagues integrate the available data and propose a role for PI 3-kinase in T-cell activation and costimulation.

Therapeutic Potential of Phosphoinositide 3-Kinase Inhibitors

At least one Holy Grail for many academic researchers and pharmaceutical research divisions alike has been to identify therapeutically useful selective PI3K inhibitors. There are several different but closely related PI3Ks which are thought to have distinct biological roles. Until now, however, researchers have been frustrated by poor selectivity of the available pharmacological inhibitors, which are unable to distinguish the different isoforms of PI3K adequately. Fortunately, recently published work gives cause for optimism; there are now several patent specifications published that describe new PI3K inhibitors, including some that are more selective for the delta isoform of PI3K. Given the involvement of PI3Ks in a plethora of biological settings, such isoform-selective inhibitors may have immense potential use for the treatment of patients with inflammatory and autoimmune disorders as well as cancer and cardiovascular diseases.

Phosphoinositide 3-kinase: a key biochemical signal for cell migration in response to chemokines

Chemokines can couple to distinct signalling pathways that have been demonstrated to mediate not only migration, but also cell growth and transcriptional activation. One particular signalling pathway, namely that controlled by the lipid kinase phosphoinositide 3-kinase (PI3K), has been the focus of much attention with respect to its activation by chemokine receptors and the role it plays in regulating cell migration. Identification of PI3K is arguably one of the most exciting recent developments in biochemical signalling. Pharmacological and genetic studies have now convincingly shown that both CC and CXC chemokines stimulate PI3K-dependent chemotaxis of inflammatory cells such as eosinophils, macrophages, neutrophils and T lymphocytes. This review considers the role of specific sub-classes of PI3Ks (e.g. the p85/p110 heterodimer, PI3Kgamma and PI3K-C2alpha) as well as their downstream effector targets in mediating chemokine-stimulated cell migration.

Isoform-specific phosphoinositide 3-kinase inhibitors as therapeutic agents

The phosphoinositide 3-kinase (PI3K) family of enzymes consists of several closely related isoforms that are thought to have distinct biological roles. Until now, researchers have been frustrated by poor selectivity of the available pharmacological inhibitors, which are unable to distinguish adequately the activities of different PI3K isoforms. Recently published patent specifications describe new PI3K inhibitors, including several that are selective for the PI3Kdelta isoform. There is now cautious optimism that isoform-selective PI3K inhibitors will provide new avenues for therapeutic applications in a range of diseases.

Chemokine signalling : pivoting around multiple phosphoinositide 3-kinases

The role of chemokines in mediating directional cell migration is well established, but more recently it has become evident that chemokines are able to couple to distinct signalling pathways that are involved in not only chemotaxis, but also cell growth and transcriptional activation. The signalling pathway controlled by the phosphoinositide 3‐kinase (PI3K) family of lipid kinases has been the focus of much attention with respect to their role in chemokine‐mediated functional responses. Indeed, there now exists convincing biochemical, pharmacological and genetic evidence that both CC and CXC chemokines stimulate PI3K‐dependent chemotaxis of inflammatory cells such as eosinophils, macrophages, neutrophils and T lymphocytes. This review considers the role of individual PI3Ks (e.g. the p85/p110 heterodimer, PI3Kγ and PI3KC2α) as well their downstream effector targets in mediating chemokine‐stimulated cell migration.

Evidence that SHIP-1 contributes to phosphatidylinositol 3,4,5-trisphosphate metabolism in T lymphocytes and can regulate novel phosphoinositide 3-kinase effectors

The leukemic T cell line Jurkat is deficient in protein expression of the lipid phosphatases Src homology 2 domain containing inositol polyphosphate phosphatase (SHIP) and phosphatase and tensin homolog deleted on chromosome ten (PTEN). We examined whether the lack of expression of SHIP-1 and PTEN is shared by other leukemic T cell lines and PBLs. Analysis of a range of cell lines and PBLs revealed that unlike Jurkat cells, two other well-characterized T cell lines, namely CEM and MOLT-4 cells, expressed the 5′-phosphatase SHIP at the protein level. However, the 3-phosphatase PTEN was not expressed by CEM or MOLT-4 cells or Jurkat cells. The HUT78 cell line and PBLs expressed both SHIP and PTEN. Jurkat cells exhibited high basal levels of phosphatidylinositol 3,4,5-trisphosphate (PI(3,4,5)P3; the lipid substrate for both SHIP and PTEN) as well as saturated protein kinase B (PKB) phosphorylation. Lower levels of PI(3,4,5)P3 and higher levels of phosphatidylinositol 3,4-bisphosphate (PI(3,4)P2) as well as unsaturated constitutive phosphorylation of PKB were observed in CEM and MOLT-4 cells compared with Jurkat cells. In PBLs and HUT78 cells which express both PTEN and SHIP-1, there was no constitutive PI(3,4,5)P3 or PKB phosphorylation, and receptor stimuli were able to elicit robust phosphorylation of PKB. Expression of a constitutively active SHIP-1 protein in Jurkat cells was sufficient to reduce both constitutive PKB membrane localization and PKB phosphorylation. Together, these data indicate important differences between T leukemic cells as well as PBLs, regarding expression of key lipid phosphatases. This study provides the first evidence that SHIP-1 can influence the constitutive levels of PI(3,4,5)P3 and the activity of downstream phosphoinositide 3-kinase effectors in T lymphocytes.

Phosphoinositide 3-kinases in T lymphocyte activation

Biochemical experiments have established that the metabolism of inositol phospholipids by phosphoinositide 3-kinases (PI3Ks) and lipid-phosphatases is triggered by many receptors that control T lymphocyte function, including antigen-receptors, costimulatory molecules, cytokines and chemokines. Novel effectors of PI3K have been identified in the immune system and shown to be important in the control of lymphocyte activation. Moreover, key lipid-phosphatases have been identified that act to terminate or modulate PI3K signalling in cells of the immune system.

Autophosphorylation of p110delta phosphoinositide 3-kinase: a new paradigm for the regulation of lipid kinases in vitro and in vivo.

Phosphoinositide 3‐kinases (PI3Ks) are lipid kinases which also possess an in vitro protein kinase activity towards themselves or their adaptor proteins. The physiological relevance of these phosphorylations is unclear at present. Here, the protein kinase activity of the tyrosine kinase‐linked PI3K, p110δ, is characterized and its functional impact assessed. In vitro autophosphorylation of p110δ completely down‐regulates its lipid kinase activity. The single site of autophosphorylation was mapped to Ser1039 at the C‐terminus of p110δ. Antisera specific for phospho‐Ser1039 revealed a very low level of phosphorylation of this residue in cell lines. However, p110δ that is recruited to activated receptors (such as CD28 in T cells) shows a time‐dependent increase in Ser1039 phosphorylation and a concomitant decrease in associated lipid kinase activity. Treatment of cells with okadaic acid, an inhibitor of Ser/Thr phosphatases, also dramatically increases the level of Ser1039‐phosphorylated p110δ. LY294002 and wortmannin blocked these in vivo increases in Ser1039 phosphorylation, consistent with the notion that PI3Ks, and possibly p110δ itself, are involved in the in vivo phosphorylation of p110δ. In summary, we show that PI3Ks are subject to regulatory phosphorylations in vivo similar to those identified under in vitro conditions, identifying a new level of control of these signalling molecules.

Pretreatment frequency of circulating IL-17+CD4+ T-cells, but not Tregs, correlates with clinical response to whole-cell vaccination in prostate cancer patients

The aim of this study was to determine the prognostic implications of the pretreatment level of Th17 cells compared with regulatory T‐cell status in prostate cancer patients receiving active whole cell immunotherapy. Ten‐color flow cytometry was used to analyze IL‐17‐producing CD4+ T‐cells in the peripheral blood of hormone‐resistant non‐bone metastatic prostate cancer patients prior to immunotherapy with an allogeneic whole‐cell vaccine. Surface expression of the chemokine receptors CCR4 and CCR6 was used to further subdivide IL‐17‐producing cells into subsets with distinct homing properties. The frequency of circulating regulatory T‐cells (Tregs), defined as CD3+CD4+CD127loFoxp3+CD25+ was compared in the same patients. The frequency of CCR4−IL‐17+CD4+ T‐cells prevaccination inversely correlated with time to disease progression (TTP) in 23 prostate cancer patients. Furthermore, responder (R) patients with statistically significant reductions in PSA velocity (PSAV) in response to the immunotherapy (n = 9), showed a Th17 profile similar to healthy male controls and significantly different from non‐responder (NR) patients (n = 14) (i.e., those without any significant reduction in PSAV). In contrast, the frequency of Tregs in peripheral blood in PSA‐R (n = 11) and ‐NR (n = 14) patients was similar (but in both cases, significantly higher than in age‐matched healthy men). Accordingly, there was no significant correlation between frequency of Tregs and TTP in these late‐stage prostate cancer patients undergoing active immunotherapy. These data imply an important role for IL‐17‐producing helper T‐cells in cancer immunology and highlight their potential use as a pretreatment screen to ensure appropriate treatment is offered to hormone‐resistant prostate cancer patients.